TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00983749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full-pressure ECP
Description: A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
Study: NCT00743847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
Study: NCT01317004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: 0.5 mg/day oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard MS DMT
Description: Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
Study: NCT03876496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensableCare System
Description: The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented.
Study: NCT00499343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 150 mg/m\^2 given intravenously over 2 hours every 12 hours x 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m\^2 injection given every evening till the completion of apheresis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isophosphamide
Description: 10 g/m\^2 given intravenously continuous infusion over 72 hours.
Study: NCT00983749

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-pressure ECP
Description: A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
Study: NCT00499343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isophosphamide
Description: 10 g/m\^2 given intravenously continuous infusion over 72 hours.
Study: NCT02130245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early cholecystectomy
Description: Early laparoscopic cholecystectomy for acute cholecystitis after admission

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cholecystectomy
Description: Laparoscopic cholecystectomy well be done after a period on conservation
Study: NCT02957955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
Study: NCT00499343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days +1 (375 mg/m\^2) and +8 (1000 mg/m\^2) given intravenously.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Peripheral blood stem cell collection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Peripheral blood stem cell collection.
Study: NCT02951793

Intervention type: OTHER
Intervention: AUDIT-C
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C\>4 versus AUDIT-C of 4 or below.

Intervention type: OTHER
Intervention: AUDIT-C
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C\>4 versus AUDIT-C of 4 or below.

Intervention type: OTHER
Intervention: Smoking history
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)

Intervention type: OTHER
Intervention: Smoking history
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)

Intervention type: OTHER
Intervention: Prior psychotropic medication use
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
Study: NCT04073342

Intervention type: GENETIC
Intervention: Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
Description: Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).

Intervention type: GENETIC
Intervention: Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
Description: Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
Study: NCT06182345

Intervention type: PROCEDURE
Intervention: spray skin
Description: autologous skin cell suspension combined with skin graft

Intervention type: PROCEDURE
Intervention: skin graft
Description: skin graft
Study: NCT02453061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin oil
Description: Triheptanoin oil orally administered at 1g/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil orally administered at 1g/kg/day
Study: NCT03363347

Intervention type: DRUG
Intervention: Redifferentiation with retinoid acid
Description: In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
Study: NCT02677077

Intervention type: DRUG
Intervention: natalizumab
Description: Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic

Intervention type: DRUG
Intervention: natalizumab
Description: Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
Study: NCT02557126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URC102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03508947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium Chloride
Study: NCT01543997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Education
Description: This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
Study: NCT01784523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study: NCT02453984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-MPDL-3280A-PET scans
Description: 89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
Study: NCT02605746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib 750mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib 750mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib 750mg
Study: NCT00880022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexitouch System
Description: ( 10 to 30 treatments depending on group assignment)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch System
Description: ( 10 to 30 treatments depending on group assignment)
Study: NCT01620970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03446962
Description: PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
Study: NCT02951793

Intervention type: OTHER
Intervention: Prior psychotropic medication use
Description: Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
Study: NCT00259428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone (SR33589)
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT01482299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability.
Study: NCT01642953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early recovery
Description: The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
Study: NCT01141166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional and a rehabilitation plan.
Description: The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
Study: NCT02261831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: obese patients
Description: collection of blood sampling and biopsies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diabetic patients
Description: collection of blood sampling and biopsies
Study: NCT03067545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Step rate increase
Description: increase the step rate during running by 10% steps per minute
Study: NCT03113747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASCs
Description: 1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
Study: NCT02689570

Intervention type: OTHER
Intervention: observational
Description: no interventions; observational study
Study: NCT01173978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steroid hormone
Description: Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Study: NCT00976690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine OR Mesalazine
Description: Azathioprine : 2mg/kg/day Mesalazine : 4g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine OR Mesalazine
Description: Azathioprine : 2mg/kg/day Mesalazine : 4g/day
Study: NCT01677299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFB0027 (metformin delayed release)
Description: Comparison of enteric-coating to assess effect on PK
Study: NCT02261831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients free of obesity and diabetes
Description: collection of blood sampling and biopsies
Study: NCT01677299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFB0027 (metformin delayed release)
Description: Comparison of enteric-coating to assess effect on PK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFB0027 (metformin delayed release)
Description: Comparison of enteric-coating to assess effect on PK

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFB0026 (metformin immediate-release)
Description: Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFB0026 (metformin immediate-release)
Description: Active comparator
Study: NCT02593383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.1% Adapalene + 1% Clindamycin Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.1% Adapalene + 2% Clindamycin Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + Clindamycin Hydrochloride
Description: 0.05% Adapalene + 1% Clindamycin Hydrochloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02838537

Intervention type: DRUG
Intervention: Exposure to Triptan

Intervention type: DRUG
Intervention: Exposure to Ergot
Study: NCT02007200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy Isoflavones
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02422732

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological assessments
Description: IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)
Study: NCT02261831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patients free type 2 diabetes
Description: collection of blood sampling and biopsies
Study: NCT04653155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Description: Cognitive behavioural therapy for insomnia
Study: NCT00450853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Granisetron SC followed by granisetron IV
Study: NCT02422732

Intervention type: RADIATION
Group type: OTHER
Intervention: morphological and functional MRI (fMRI)
Description: The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location.

Intervention type: RADIATION
Group type: OTHER
Intervention: morphological and functional MRI (fMRI)
Description: The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location.

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Description: Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.

Intervention type: GENETIC
Group type: OTHER
Intervention: genetic analysis
Description: Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
Study: NCT02922283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IL2-PET scan
Description: All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of non-target tissue
Description: A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
Study: NCT02140736

Intervention type: DRUG
Intervention: Epoetin biosimilar
Study: NCT03723577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibrillar collagen powder dressing
Description: A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
Study: NCT02714712

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
Study: NCT01437423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio
Description: 0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
Study: NCT00907764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: 400 ug, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: 400 ug, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson
Description: 400 ug, IV
Study: NCT04303234

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artinibsa
Description: local anaesthetic solution with a short latency time. Its high lipid solubility gives it better diffusion through soft tissues and bone and makes it highly effective for infiltrative techniques.Each ml contains 4%Articaine 1:100000.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artpharma
Description: Its a special amide local anesthetic contain 4% articaine with epinephrine 1/200000 as a vasoconstrictor ,Contains only sulfite as a stabilizer (max 0.31 mg)